Updated safety and efficacy from a phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC) Meeting Abstract
| Authors: | Wolpin, B.; Hong, D.; Spira, A.; Starodub, A.; Park, W.; Sommerhalder, D.; Valerin, J.; Barve, M.; Punekar, S.; Pelster, M.; Herzberg, B.; Azad, N.; Aung, K.; Hecht, J. R.; Cheng, L.; Vora, R.; Salman, Z.; Zhang, Y.; Lin, T.; Garrido-Laguna, I. |
| Abstract Title: | Updated safety and efficacy from a phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC) |
| Meeting Title: | 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 211 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Oct 23-25 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-10-01 |
| Start Page: | S183 |
| End Page: | S184 |
| Language: | English |
| ACCESSION: | WOS:001345547300464 |
| DOI: | 10.1016/j.ejca.2024.114992 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 514LBA (PB-514) -- Article number: 114992 -- Source: Wos |
